Cited by 46Viral Infectious Diseases and Gene Expression in InsectsProtein purification and stabilityTransgenic Plants and Applications

Genetic engineering approaches to improve posttranslational modification of biopharmaceuticals in different production platforms

Open access
Amann, Thomas, Schmieder, Valerie, Faustrup Kildegaard, Helene, Borth, Nicole, Andersen, Mikael Rørdam·2019·Biotechnology and Bioengineering

Abstract

The number of approved biopharmaceuticals, where product quality attributes remain of major importance, is increasing steadily. Within the available variety of expression hosts, the production of biopharmaceuticals faces diverse limitations with respect to posttranslational modifications (PTM), while different biopharmaceuticals demand different forms and specifications of PTMs for proper functionality. With the growing toolbox of genetic engineering technologies, it is now possible to address general as well as host‐ or biopharmaceutical‐specific product quality obstacles. In this review, we present diverse expression systems derived from mammalians, bacteria, yeast, plants, and insects as well as available genetic engineering tools. We focus on genes for knockout/knockdown and overexpression for meaningful approaches to improve biopharmaceutical PTMs and discuss their applicability as well as future trends in the field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/bit.27101

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Murine cell lines NS0 and Sp2/0 produce glycan structures similar to humans but also produce immunogenic epitopes such as Galα(1-3)Gal and have high NeuGc sialic acid, which is why they are less commonly used for biotherapeutic production.

    “while murine cell lines such as NS0 and Sp2/0 also produce glycan structures similar to humans, they also produce immunogenic epitopes such as the Galα(1–3)Gal epitope and they have a high content of NeuGc sialic acid, which is why they are less commonly used for biotherapeutic production [1,73].”

    From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [73]

    The Accepted Article passage (page unavailable) says biopharmaceuticals from mouse cell lines have a higher proportion of Neu5Gc than those from CHO cells, and identifies this as a major reason mouse lines stopped being used for human antibody production. The passages do not establish the specific claims about NS0 and Sp2/0, their human-like glycans, or their production of the Galα(1–3)Gal epitope; the source also speaks specifically about human antibody production rather than biotherapeutics generally. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In CHO cells, knock down, knock out and overexpression of glycosylation enzymes and NSD transporters have been used in biotherapeutic functional studies and for development of biobetters.

    “In CHO cells, the knock down (KD), knock out (KO) and overexpression (OE) of glycosylation enzymes and NSD transporters have been used in biotherapeutic functional studies and for the development of biobetters, as summarised in Figure 2 [73,74].”

    From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [73]

    Section 5.1.1 and Table 2 describe knockdown, knockout and overexpression of glycosylation-related enzymes in CHO cells to alter biopharmaceutical glycosylation and product properties. The passages do not establish the claimed use of NSD transporter engineering in CHO cells; Table 2 lists overexpression of SLC35A2 in yeast instead. Page numbers are unavailable in our copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • The availability of genomic sequences has enabled CHO cell engineering with unprecedented precision using engineered nucleases including ZFNs, TALENs and CRISPR.

    “The availability of genomic sequences has enabled CHO cell engineering with unprecedented precision using engineered nucleases, including zinc finger nucleases (ZFNs) and transcription activator like nucleases (TALENs) and the clustered regularly interspaced short palindromic repeats (CRISPR) system [71–73,75,76].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Shawn Liu, X., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., … Jaenisch, R. (2016). Editing DNA methylation in the mammalian genome. Cell, 167(1), 233.
  2. Yang, Z., Bennett, E. P., Jørgensen, B., Drew, D. P., Arigi, E., Mandel, U., … Petersen, B. L. (2012). Toward stable genetic engineering of human O-glycosylation in plants. Plant Physiology, 160(1), 450-463.

Cited by

Sorted by citations

Authors
Amann, T., Schmieder, V., Faustrup Kildegaard, H., Borth, N., & Andersen, M. R.
Affiliations
  • Novo Nordisk Foundation (DK)
  • Austrian Centre of Industrial Biotechnology (Austria) (AT)
  • The Novo Nordisk Foundation Center for Biosustainability Technical University of Denmark Kongens Lyngby Denmark
  • BOKU University (AT)
  • Technical University of Denmark (DK)
Corresponding author
Andersen, Mikael Rørdam
Venue
Biotechnology and Bioengineering
Publisher
Wiley
Published
2019-07-21
Volume
116
Issue
10
Pages
2778-2796
ISSN
  • 0006-3592 (ISSN-L)
  • 1097-0290
OpenAlex
W2955046473
Cited by
46
References
224
Citations by year
2026: 3 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 11 · 2021: 10 · 2020: 6 · 2019: 4
FWCI
0.68
Type
journal article
Language
en
Open access
Locations
  • Biotechnology and Bioengineering (publishedVersion)
  • PubMed (publishedVersion)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, other-oa)
Funders
Novo Nordisk Fonden (NNF10CC1016517)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
Keywords
post-translational modification, biopharmaceuticals, genetic engineering, expression systems, overexpression, product quality attributes, mammalian cell expression systems, yeast expression system, plant expression systems, insect expression system, prokaryotic expression
MeSH terms
Animals, Biological Products, Genetic Engineering, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review